Literature DB >> 25126337

First Generic ARB Approval Draws a Wave of Comparative Studies.

Dalia Buffery.   

Abstract

Year:  2011        PMID： 25126337      PMCID： PMC4106563     

Source DB:  PubMed          Journal:  Am Health Drug Benefits        ISSN： 1942-2962


× No keyword cloud information.
  3 in total

Review 1.  Comparative clinical- and cost-effectiveness of candesartan and losartan in the management of hypertension and heart failure: a systematic review, meta- and cost-utility analysis.

Authors:  A M Grosso; P N Bodalia; R J Macallister; A D Hingorani; J C Moon; M A Scott
Journal:  Int J Clin Pract       Date:  2011-02-01       Impact factor: 2.503

2.  Association of candesartan vs losartan with all-cause mortality in patients with heart failure.

Authors:  Maria Eklind-Cervenka; Lina Benson; Ulf Dahlström; Magnus Edner; Mårten Rosenqvist; Lars H Lund
Journal:  JAMA       Date:  2011-01-12       Impact factor: 56.272

3.  A randomized, double-blind, forced-titration study to compare olmesartan medoxomil versus losartan potassium in patients with stage 1 and 2 hypertension.

Authors:  Matthew R Weir; Henry A Punzi; John M Flack; Kathy A Stoakes; Kathleen J Chavanu; Wei Li; Robert Dubiel
Journal:  Postgrad Med       Date:  2011-01       Impact factor: 3.840
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.